VTV Therapeutics Inc-CL A (NASDAQ:VTVT) Reports Wider Q2 2025 Loss Amid Clinical-Stage Progress

VTV THERAPEUTICS INC-CL A (NASDAQ:VTVT) reported its second-quarter 2025 financial results, posting a net loss per share of $0.92, which was wider than the analyst consensus estimate of a $0.8415 loss. Revenue for the quarter came in at $0, matching expectations. The company’s lack of revenue reflects its clinical-stage status, with no commercialized products currently generating sales.

Key Financial Takeaways

• Earnings Miss: The reported EPS of -$0.92 was approximately 9.3% worse than the estimated -$0.8415.
• Revenue In Line: No revenue was recorded, consistent with analyst projections.
• Cash Burn Continues: As a pre-revenue biotech firm, vTv remains reliant on funding to advance its pipeline.

Market Reaction

Following the earnings release, shares of vTv Therapeutics saw a modest after-hours gain of 3.52%, suggesting that investors may be looking past the wider-than-expected loss and focusing instead on clinical progress. Over the past month, the stock has been relatively stable, with a slight decline of 2.75%, while the two-week performance shows a more pronounced drop of 14.9%. The immediate uptick post-earnings could indicate cautious optimism around the company’s ongoing trials.

Corporate Update Highlights

The press release emphasized progress in the company’s lead candidate, cadisegliatin (TTP399), a potential adjunctive therapy for type 1 diabetes:

• The first participant has been randomized in the Phase 3 CATT1 trial, with data expected in the second half of 2026.
• No revenue-generating milestones were announced, keeping the focus on clinical development rather than near-term commercialization.

Looking Ahead

Analysts expect vTv to continue posting losses, with full-year 2025 EPS projected at -$3.6414 and no sales anticipated. For Q3 2025, the consensus EPS estimate stands at -$0.918, again with zero revenue expected. The lack of a revenue outlook in the press release does not alter expectations, as the company’s valuation remains tied to clinical trial outcomes rather than near-term financial performance.

For a deeper dive into vTv Therapeutics’ earnings and estimates, visit the earnings page.

Disclaimer: This article is not investment advice. Investors should conduct their own research or consult a financial advisor before making decisions.